Temat: "lenalidomide" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity.
Autorzy :: Germans SK; Department of Pathology, University of Texas Southwestern Medical Center, Dallas.
Kulak O; Department of Pathology, University of Texas Southwestern Medical Center, Dallas.
Koduru P; Department of Genomics and Molecular Pathology, University of Texas Southwestern Medical Center, Dallas.
Oliver D; Department of Genomics and Molecular Pathology, University of Texas Southwestern Medical Center, Dallas.
Gagan J; Department of Genomics and Molecular Pathology, University of Texas Southwestern Medical Center, Dallas.
Patel P; Department of Internal Medicine, Hematology and Oncology Division, University of Texas Southwestern Medical Center, Dallas.
Anderson LD Jr; Department of Internal Medicine, Hematology and Oncology Division, University of Texas Southwestern Medical Center, Dallas.
Fuda FS; Department of Pathology, University of Texas Southwestern Medical Center, Dallas.
Chen W; Department of Pathology, University of Texas Southwestern Medical Center, Dallas.
Jaso JM; Department of Pathology, University of Texas Southwestern Medical Center, Dallas.; Pokaż więcej
Źródło :: American journal of clinical pathology [Am J Clin Pathol] 2020 Nov 04; Vol. 154 (6), pp. 816-827.
Typ publikacji :: Case Reports; Journal Article; Review
MeSH Terms :: Immunologic Factors*
Lenalidomide/*adverse effects
Multiple Myeloma/*therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*chemically induced
Adult ; Antineoplastic Agents/therapeutic use ; Bone Marrow/chemistry ; Bone Marrow/pathology ; Cytogenetic Analysis ; Fatal Outcome ; High-Throughput Nucleotide Sequencing ; Humans ; Lenalidomide/therapeutic use ; Male ; Middle Aged ; Neoplasm, Residual ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Recurrence ; Remission Induction ; Stem Cell Transplantation
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Autorzy :: Takezako N; National Hospital Organization Disaster Medical Center, 3256 Midori, Tachikawa, Tokyo, Japan. .
Kosugi H; Ogaki Municipal Hospital, Ogaki, Japan.
Matsumoto M; National Hospital Organization, Shibukawa Medical Center, Shibukawa, Japan.
Iida S; Nagoya City University Hospital, Nagoya, Japan.
Ishikawa T; Kobe City Medical Center, Kobe, Japan.
Kondo Y; Kanazawa University Hospital, Kanazawa, Japan.
Ando K; Tokai University School of Medicine, Isehara, Japan.
Miki H; Tokushima University Hospital, Tokushima, Japan.
Matsumura I; Kindai University Hospital, Osaka-Sayama, Japan.
Sunami K; National Hospital Organization Okayama Medical Center, Okayama, Japan.
Teshima T; Hokkaido University Hospital, Sapporo, Japan.
Iwasaki H; National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Onishi Y; Tohoku University Hospital, Sendai, Japan.
Kizaki M; Saitama Medical Center, Saitama Medical University, Kawagoe-shi, Japan.
Izutsu K; National Cancer Center Hospital, Tokyo, Japan.
Maruyama D; National Cancer Center Hospital, Tokyo, Japan.
Tobinai K; National Cancer Center Hospital, Tokyo, Japan.
Ghori R; Merck & Co., Inc., Kentilworth, NJ, USA.
Farooqui M; Merck & Co., Inc., Kentilworth, NJ, USA.
Liao J; Merck & Co., Inc., Kentilworth, NJ, USA.
Marinello P; Merck & Co., Inc., Kentilworth, NJ, USA.
Matsuda K; MSD K.K, Tokyo, Japan.
Koh Y; MSD K.K, Tokyo, Japan.
Shimamoto T; MSD K.K, Tokyo, Japan.
Suzuki K; Japanese Red Cross Medical Center, Tokyo, Japan.; Pokaż więcej
Źródło :: International journal of hematology [Int J Hematol] 2020 Nov; Vol. 112 (5), pp. 640-649. Date of Electronic Publication: 2020 Sep 19.
Typ publikacji :: Journal Article
MeSH Terms :: Randomized Controlled Trials as Topic*
Risk Assessment*
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Dexamethasone/*administration & dosage
Lenalidomide/*administration & dosage
Multiple Myeloma/*drug therapy
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Asian Continental Ancestry Group ; Biosimilar Pharmaceuticals ; Disease-Free Survival ; Female ; Humans ; Lenalidomide/adverse effects ; Male ; Multiple Myeloma/mortality
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
Autorzy :: Ladetto M; Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. Electronic address: .
Cortelazzo S; Unit of Oncology-Haematology, Humanitas Gavazzeni, Bergamo, Italy.
Ferrero S; Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino, Italy.
Evangelista A; Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino, Italy.
Mian M; Department of Haematology and CBMT, Bolzano Hospital, Bolzano, Italy.
Tavarozzi R; Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Zanni M; Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Cavallo F; Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino, Italy.
Di Rocco A; Department of Translational and Precision Medicine, Sapienza University of Rome, Roma, Italy.
Stefoni V; Institute of Haematology L. e A. Seràgnoli, University of Bologna, Bologna, Italy.
Pagani C; Department of Haematology, ASST-Spedali Civili Hospital, Brescia, Italy.
Re A; Department of Haematology, ASST-Spedali Civili Hospital, Brescia, Italy.
Chiappella A; Azienda Ospedaliero, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino, Italy.
Balzarotti M; Haematology Unit, Humanitas Clinical and Research Center - IRCCS - Rozzano, Milano, Italy.
Zilioli VR; Division of Haematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Gomes da Silva M; Haematology Unit, Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
Arcaini L; Division of Haematology, Fondazione IRCCS Policlinico S Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Molinari AL; Department of Haematology, Infermi Hospital, Rimini, Italy.
Ballerini F; University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'Oncologia, Genova, Italy.
Ferreri AJM; Lymphoma Unit, Department of Onco-Haematology, IRCCS San Raffaele Scientific Institute, Milano, Italy.
Puccini B; Department of Haematology, University of Florence, Firenze, Italy.
Benedetti F; Haematology University Division, Verona Hospital, Verona, Italy.
Stefani PM; SC di Ematologia - Presidio Ospedaliero Ca' Foncello, Treviso, Italy.
Narni F; Department of Medical and Surgical Sciences, Section of Haematology, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria Policlinico, Modena, Italy.
Casaroli I; Haematology Unit, ASST Monza San Gerardo, Monza, Italy.
Stelitano C; Department of Haematology, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy.
Ciccone G; Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino, Italy.
Vitolo U; Azienda Ospedaliero, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino, Italy.
Martelli M; Department of Translational and Precision Medicine, Sapienza University of Rome, Roma, Italy.; Pokaż więcej
Źródło :: The Lancet. Haematology [Lancet Haematol] 2021 Jan; Vol. 8 (1), pp. e34-e44. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji :: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :: Hematopoietic Stem Cell Transplantation*
Lymphoma, Mantle-Cell*/blood
Lymphoma, Mantle-Cell*/mortality
Lymphoma, Mantle-Cell*/therapy
Maintenance Chemotherapy*
Lenalidomide/*administration & dosage
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Female ; Humans ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Platelet Count ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Survival Rate ; Transplantation, Autologous ; Vincristine/administration & dosage ; Vincristine/adverse effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Autorzy :: Susek KH; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Gran C; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.
Ljunggren HG; Center for Infectious Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Alici E; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Nahi H; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.; Pokaż więcej
Źródło :: European journal of haematology [Eur J Haematol] 2020 Dec; Vol. 105 (6), pp. 751-754. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies, Monoclonal/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Coronavirus Infections/*diagnosis
Dexamethasone/*adverse effects
Lenalidomide/*adverse effects
Multiple Myeloma/*diagnosis
Pneumonia, Viral/*diagnosis
Thalidomide/*adverse effects
Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Betacoronavirus/pathogenicity ; COVID-19 ; Cohort Studies ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Dexamethasone/administration & dosage ; Disease Progression ; Female ; Humans ; Immunomodulation ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Multiple Myeloma/mortality ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Prognosis ; Remission Induction ; SARS-CoV-2 ; Severity of Illness Index ; Survival Analysis ; Thalidomide/administration & dosage ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Mechanisms of lenalidomide sensitivity and resistance.
Autorzy :: Martinez-Høyer S; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden. Electronic address: .
Karsan A; Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada; Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: .; Pokaż więcej
Źródło :: Experimental hematology [Exp Hematol] 2020 Nov; Vol. 91, pp. 22-31. Date of Electronic Publication: 2020 Oct 09.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Antineoplastic Agents/*pharmacology
Immunologic Factors/*pharmacology
Lenalidomide/*pharmacology
Adaptor Proteins, Signal Transducing/antagonists & inhibitors ; Anemia, Macrocytic/drug therapy ; Anemia, Macrocytic/physiopathology ; Angiogenesis Inhibitors/pharmacology ; Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Agents/therapeutic use ; Autophagy/drug effects ; Cell Differentiation/drug effects ; Chromosome Deletion ; Chromosomes, Human, Pair 5 ; Cytokines/metabolism ; Disease Progression ; Drug Resistance, Neoplasm/physiology ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Ikaros Transcription Factor/antagonists & inhibitors ; Immunologic Factors/therapeutic use ; Lenalidomide/therapeutic use ; Megakaryocytes/drug effects ; Multiple Myeloma/drug therapy ; Multiple Myeloma/physiopathology ; Neoplasm Proteins/antagonists & inhibitors ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/physiopathology ; Phosphoprotein Phosphatases/antagonists & inhibitors ; Ubiquitin-Protein Ligases/antagonists & inhibitors ; Ubiquitin-Protein Ligases/physiology
SCR Disease Name :: Chromosome 5q Deletion Syndrome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report.
Autorzy :: Batgi H; Hematology Clinic and Bone Marrow Transplantation Unit, University of Health Sciences Ankara, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.
Dal MS; Hematology Clinic and Bone Marrow Transplantation Unit, University of Health Sciences Ankara, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.
Merdin A; Hematology Clinic and Bone Marrow Transplantation Unit, University of Health Sciences Ankara, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.
Kızıl Çakar M; Hematology Clinic and Bone Marrow Transplantation Unit, University of Health Sciences Ankara, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.
Yiğenoğlu TN; Hematology Clinic and Bone Marrow Transplantation Unit, University of Health Sciences Ankara, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.
Altuntaş F; Hematology Clinic and Bone Marrow Transplantation Unit, University of Health Sciences Ankara, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey.; Pokaż więcej
Źródło :: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Sep; Vol. 26 (6), pp. 1499-1500. Date of Electronic Publication: 2020 Feb 06.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Colitis, Ischemic/*chemically induced
Lenalidomide/*adverse effects
Multiple Myeloma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/administration & dosage ; Hematopoietic Stem Cell Transplantation ; Humans ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Transplantation, Autologous
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report.
Autorzy :: Hu S; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, China.
Zou D
Zhou D
Zhang Y
Wang W
Zhang W; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2020 Oct 23; Vol. 99 (43), pp. e22788.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Aminopyridines/*therapeutic use
Benzamides/*therapeutic use
Lenalidomide/*therapeutic use
Lymphoma, Non-Hodgkin/*drug therapy
Aged ; Aminopyridines/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzamides/administration & dosage ; Female ; Humans ; Lenalidomide/administration & dosage ; Lymphoma, Large B-Cell, Diffuse/pathology ; Lymphoma, Non-Hodgkin/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Salvage Therapy
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.
Autorzy :: Schoenbeck KL; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Wildes TM; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.; Pokaż więcej
Źródło :: Clinical interventions in aging [Clin Interv Aging] 2020 May 04; Vol. 15, pp. 619-633. Date of Electronic Publication: 2020 May 04 (Print Publication: 2020).
Typ publikacji :: Journal Article; Review
MeSH Terms :: Immunologic Factors/*therapeutic use
Lenalidomide/*therapeutic use
Multiple Myeloma/*drug therapy
Aged ; Antibodies, Monoclonal/therapeutic use ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown.
Autorzy :: Jin YH; State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Lu MC; State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Wang Y; State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Shan WX; State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Wang XY; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
You QD; State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Jiang ZY; State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.; Pokaż więcej
Źródło :: Journal of medicinal chemistry [J Med Chem] 2020 May 14; Vol. 63 (9), pp. 4644-4654. Date of Electronic Publication: 2020 Mar 19.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Azo Compounds/*pharmacology
Dasatinib/*analogs & derivatives
Dasatinib/*pharmacology
Lenalidomide/*analogs & derivatives
Lenalidomide/*pharmacology
Adaptor Proteins, Signal Transducing/metabolism ; Azo Compounds/chemical synthesis ; Azo Compounds/radiation effects ; Cell Line, Tumor ; Dasatinib/radiation effects ; Fusion Proteins, bcr-abl/metabolism ; Humans ; Lenalidomide/radiation effects ; Ligands ; Proteolysis/drug effects ; Stereoisomerism ; Ubiquitin-Protein Ligases ; Ubiquitination/drug effects ; Ultraviolet Rays
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Distinct mutational pattern of myelodysplastic syndromes with and without 5q- treated with lenalidomide.
Autorzy :: Adema V; MDS Research Group, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain.; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Palomo L; MDS Research Group, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain.
Toma A; Assistance Publique - Hôpitaux de Paris, Service Hematologie Clinique, Hôpital Universitaire Henri Mondor, Creteil, France.
Kosmider O; Assistance Publique-Hopitaux de Paris, Service d'Hematologie Biologique, Hopitaux Universitaires Paris Centre, Paris, France.
Fuster-Tormo F; MDS Research Group, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain.
Benito R; Unidad de Diagnóstico Molecular y Celular del Cáncer, IBSAL, IBMCC-Centro de Investigación del Cáncer (USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.; Department of Medicine, Universidad de Salamanca, Salamanca, Spain.; Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain.
Salgado R; Laboratorio de Citogenetica, Servicio de Hematología, Hospital Universitario fundación Jimenez Díaz, Madrid, Spain.
Such E; Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.; Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Genetics Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Larrayoz MJ; Department of Genetics, School of Medicine, University of Navarra, IDISNA, Pamplona, Spain.
Xicoy B; Hematology Service, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain.
Hernandez-Sanchez JM; Unidad de Diagnóstico Molecular y Celular del Cáncer, IBSAL, IBMCC-Centro de Investigación del Cáncer (USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.; Department of Medicine, Universidad de Salamanca, Salamanca, Spain.; Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain.
Maietta P; Scientific & Innovation Department, Nimgenetics, Madrid, Spain.
Neef A; Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.; Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Genetics Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Fontenay M; Assistance Publique-Hopitaux de Paris, Service d'Hematologie Biologique, Hopitaux Universitaires Paris Centre, Paris, France.
Ibañez M; Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.; Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Hematology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Genetics Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Diez-Campelo M; Unidad de Diagnóstico Molecular y Celular del Cáncer, IBSAL, IBMCC-Centro de Investigación del Cáncer (USAL-CSIC), Universidad de Salamanca, Salamanca, Spain.; Department of Medicine, Universidad de Salamanca, Salamanca, Spain.; Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain.
Alvarez S; Scientific & Innovation Department, Nimgenetics, Madrid, Spain.
Maciejewski JP; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Fenaux P; Assistance Publique-Hopitaux de Paris, Service d'Hematologie Biologique, Hopitaux Universitaires Paris Centre, Paris, France.
Sole F; MDS Research Group, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain.; Pokaż więcej
Źródło :: British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (4), pp. e133-e137. Date of Electronic Publication: 2020 Mar 09.
Typ publikacji :: Letter; Research Support, Non-U.S. Gov't
MeSH Terms :: Lenalidomide/*therapeutic use
Myelodysplastic Syndromes/*drug therapy
Humans ; Lenalidomide/pharmacology ; Mutation
: Raport

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.
Autorzy :: Suichi T; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
Misawa S; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
Nagashima K; Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Japan.
Sato Y; Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Japan.
Iwai Y; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
Katayama K; Clinical Research Center, Chiba University Hospital, Japan.
Sekiguchi Y; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
Shibuya K; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
Amino H; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
Suzuki YI; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
Tsuneyama A; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
Nakamura K; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
Kuwabara S; Department of Neurology, Graduate School of Medicine, Chiba University, Japan.; Pokaż więcej
Źródło :: Internal medicine (Tokyo, Japan) [Intern Med] 2020 May 01; Vol. 59 (9), pp. 1149-1153. Date of Electronic Publication: 2020 Feb 01.
Typ publikacji :: Journal Article; Randomized Controlled Trial
MeSH Terms :: Lenalidomide/*therapeutic use
POEMS Syndrome/*drug therapy
Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Immunologic Factors ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; POEMS Syndrome/blood ; Prospective Studies ; Thalidomide/administration & dosage ; Thalidomide/therapeutic use ; Treatment Outcome ; Vascular Endothelial Growth Factor A/blood ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.
Autorzy :: Cohen OC; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
Sharpley F; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
Gillmore JD; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
Lachmann HJ; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
Sachchithanantham S; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.; University College London Hospitals NHS Trust, London, UK.
Mahmood S; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.; University College London Hospitals NHS Trust, London, UK.
Fontana M; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
Whelan CJ; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
Martinez-Naharro A; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
Kyriakou C; University College London Hospitals NHS Trust, London, UK.
Rabin N; University College London Hospitals NHS Trust, London, UK.
Popat R; University College London Hospitals NHS Trust, London, UK.
Yong K; University College London Hospitals NHS Trust, London, UK.
Cheesman S; University College London Hospitals NHS Trust, London, UK.
Shah R; University College London Hospitals NHS Trust, London, UK.
Hawkins PN; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
Wechalekar AD; National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.; University College London Hospitals NHS Trust, London, UK.; Pokaż więcej
Źródło :: British journal of haematology [Br J Haematol] 2020 May; Vol. 189 (4), pp. 643-649. Date of Electronic Publication: 2020 Jan 26.
Typ publikacji :: Journal Article
MeSH Terms :: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Boron Compounds/*therapeutic use
Dexamethasone/*therapeutic use
Glycine/*analogs & derivatives
Immunoglobulin Light-chain Amyloidosis/*drug therapy
Lenalidomide/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Boron Compounds/pharmacology ; Dexamethasone/pharmacology ; Female ; Glycine/pharmacology ; Glycine/therapeutic use ; Humans ; Immunoglobulin Light-chain Amyloidosis/pathology ; Lenalidomide/pharmacology ; Male ; Middle Aged ; Neoplasm Recurrence, Local
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
Autorzy :: Thanarajasingam G; Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: .
Leonard JP; Division of Hematology and Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA.
Witzig TE; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Blum KA; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Bartlett NL; Washington University School of Medicine, Washington University, St Louis, MO, USA.
Flowers CR; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pitcher BN; Alliance Statistics and Data Center, Duke University, Durham, NC, USA.
Jung SH; Alliance Statistics and Data Center, Duke University, Durham, NC, USA.
Atherton PJ; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Tan A; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Novotny PJ; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Dueck AC; Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ, USA.; Pokaż więcej
Źródło :: The Lancet. Haematology [Lancet Haematol] 2020 Jun; Vol. 7 (6), pp. e490-e497.
Typ publikacji :: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :: Angiogenesis Inhibitors/*toxicity
Antineoplastic Combined Chemotherapy Protocols/*toxicity
Hematologic Neoplasms/*drug therapy
Lenalidomide/*toxicity
Lymphoma, Follicular/*drug therapy
Angiogenesis Inhibitors/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Drug Tolerance/physiology ; Fatigue/chemically induced ; Fatigue/classification ; Fatigue/epidemiology ; Humans ; Infusions, Intravenous ; Lenalidomide/adverse effects ; Neutropenia/chemically induced ; Neutropenia/classification ; Neutropenia/epidemiology ; Rituximab/administration & dosage ; Rituximab/therapeutic use ; Thrombosis/chemically induced ; Thrombosis/classification ; Thrombosis/epidemiology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.
Autorzy :: He X; Department of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Dou A; Department of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Feng S; Department of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Roman-Rivera A; Department of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Hawkins C; Department of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Lawley L; Department of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC.
Zhang J; Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC.
Wunderlich M; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Mizukawa B; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH.
Halene S; Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, CT.
Patel A; Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, CT.
Fang J; Department of Drug Discovery and Biomedical Sciences, University of South Carolina College of Pharmacy, Columbia, SC. Electronic address: .; Pokaż więcej
Źródło :: Experimental hematology [Exp Hematol] 2020 Jun; Vol. 86, pp. 21-27.e2. Date of Electronic Publication: 2020 May 08.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/metabolism
Leukemia, Myeloid, Acute*/pathology
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/metabolism
Myelodysplastic Syndromes*/pathology
Cyclosporine/*pharmacology
Drug Resistance, Neoplasm/*drug effects
Lenalidomide/*pharmacology
Animals ; Apoptosis/drug effects ; Cell Line, Tumor ; Cyclosporine/agonists ; DNA-Binding Proteins/biosynthesis ; Gene Expression Regulation, Leukemic/drug effects ; Humans ; Ikaros Transcription Factor/biosynthesis ; Lenalidomide/agonists ; Mice ; Mice, Inbred NOD ; Muscle Proteins/biosynthesis ; Neoplasm Proteins/biosynthesis ; Up-Regulation/drug effects ; Xenograft Model Antitumor Assays
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
Autorzy :: Tachita T; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.; Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Kinoshita S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Ri M; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.; Department of Blood Transfusion and Cell Therapy, Nagoya City University Hospital, Nagoya, Japan.
Aoki S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Asano A; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Kanamori T; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yoshida T; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.; Department of Clinical Oncology, Nagoya Memorial Hospital, Nagoya, Japan.
Totani H; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Ito A; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Kusumoto S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Komatsu H; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yamagata K; Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Kubo K; Department of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan.
Tohkin M; Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
Fukuda S; Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Iida S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.; Pokaż więcej
Źródło :: Cancer science [Cancer Sci] 2020 Apr; Vol. 111 (4), pp. 1333-1343. Date of Electronic Publication: 2020 Mar 12.
Typ publikacji :: Journal Article
MeSH Terms :: Adaptor Proteins, Signal Transducing/*genetics
Ikaros Transcription Factor/*genetics
Lenalidomide/*administration & dosage
Multiple Myeloma/*drug therapy
alpha Karyopherins/*genetics
Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Cullin Proteins/genetics ; Dexamethasone/administration & dosage ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Immunomodulation ; Lenalidomide/adverse effects ; Male ; Methylation ; Middle Aged ; Multiple Myeloma/genetics ; Multiple Myeloma/pathology ; Mutation ; Prognosis ; Progression-Free Survival ; Ubiquitin-Protein Ligases
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Autorzy :: Montefusco V; Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Corso A; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy.
Galli M; Hematology, Papa Giovanni XXIII hospital, Bergamo, Italy.
Ardoino I; Istituto di Ricerche Farmacologiche 'Mario Negri' - IRCCS, Milan, Italy.
Pezzatti S; Hematology, San Gerardo hospital, Monza, Italy.
Carniti C; Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Patriarca F; DISM, University of Udine, Udine, Italy.
Gherlinzoni F; Hematology, Ca' Foncello hospital, Treviso, Italy.
Zambello R; Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padua, Italy.
Sammassimo S; Hematoncology, European Institute of Oncology, Milan, Italy.
Marcatti M; Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Nozza A; Oncology and Hematology Department, Istituto Clinico Humanitas, Rozzano (MI), Milan, Italy.
Crippa C; Hematology, Spedali Civili di Brescia, Brescia, Italy.
Cafro AM; Department of Oncology/Hematology, Niguarda Ca' Granda Hospital, Milan, Italy.
Baldini L; Hematology/Bone Marrow Transplantation Unit, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Ca'Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Corradini P; Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hematology, University of Milan, Milan, Italy.; Pokaż więcej
Źródło :: British journal of haematology [Br J Haematol] 2020 Mar; Vol. 188 (6), pp. 907-917. Date of Electronic Publication: 2020 Jan 02.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bortezomib/*therapeutic use
Cyclophosphamide/*therapeutic use
Dexamethasone/*therapeutic use
Lenalidomide/*therapeutic use
Multiple Myeloma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bortezomib/pharmacology ; Cyclophosphamide/pharmacology ; Dexamethasone/pharmacology ; Female ; Humans ; Lenalidomide/pharmacology ; Male ; Middle Aged ; Recurrence ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: The AUGMENT study: Lenalidomide in indolent lymphoma … balance the imbalance!
Autorzy :: Dada R; Medical Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia; Medical Oncology, College of Medicine, Al-Faisal University, Riyadh, Saudi Arabia. Electronic address: .; Pokaż więcej
Źródło :: Hematology/oncology and stem cell therapy [Hematol Oncol Stem Cell Ther] 2020 Mar; Vol. 13 (1), pp. 46-47. Date of Electronic Publication: 2019 Oct 11.
Typ publikacji :: Letter
MeSH Terms :: Angiogenesis Inhibitors/*therapeutic use
Lenalidomide/*therapeutic use
Lymphoma, Non-Hodgkin/*drug therapy
Angiogenesis Inhibitors/pharmacology ; Female ; Humans ; Lenalidomide/pharmacology ; Lymphoma, Non-Hodgkin/pathology ; Male
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile.
Autorzy :: Mo CC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Richardson PG; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Pokaż więcej
Źródło :: British journal of haematology [Br J Haematol] 2020 Feb; Vol. 188 (4), pp. 483-485. Date of Electronic Publication: 2019 Sep 30.
Typ publikacji :: Editorial; Comment
MeSH Terms :: Lenalidomide*
Multiple Myeloma*
Dexamethasone ; Humans ; Thalidomide/analogs & derivatives ; Treatment Failure
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
Autorzy :: Lonial S; Emory University, Atlanta, GA.
Jacobus S; Dana Farber Cancer Institute, Boston, MA.
Fonseca R; Mayo Clinic, Scottsdale, AZ.
Weiss M; ThedaCare Cancer Center, Appleton, WI.
Kumar S; Mayo Clinic, Rochester, MN.
Orlowski RZ; MD Anderson Cancer Center, Houston, TX.
Kaufman JL; Emory University, Atlanta, GA.
Yacoub AM; University of Kansas Cancer Center, Westwood, KS.
Buadi FK; Mayo Clinic, Rochester, MN.
O'Brien T; MetroHealth Medical Center, Cleveland, OH.
Matous JV; Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, CO.
Anderson DM; Park Nicollet Clinic, Saint Louis Park, MN.
Emmons RV; University of Louisville, Louisville, KY.
Mahindra A; Scripps Clinic Torrey Pines, La Jolla, CA.
Wagner LI; Wake Forest University Health Sciences, Winston-Salem, NC.
Dhodapkar MV; Emory University, Atlanta, GA.
Rajkumar SV; Mayo Clinic, Rochester, MN.; Pokaż więcej
Źródło :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Apr 10; Vol. 38 (11), pp. 1126-1137. Date of Electronic Publication: 2019 Oct 25.
Typ publikacji :: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :: Lenalidomide/*therapeutic use
Smoldering Multiple Myeloma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Quality of Life ; Smoldering Multiple Myeloma/mortality
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
Autorzy :: Thieblemont C; Hemato-Oncology, APHP, Hôpital Saint-Louis, Paris, France.
Howlett S; Celgene Corporation, Summit, NJ, USA.
Casasnovas RO; Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Dijon and INSERM UMR1231, Dijon, France.
Mounier N; Hématologie, Centre Hospitalier Universitaire de Nice - Hôpital de l'Archet, Nice, France.
Perrot A; Service d'Hématologie, Centre Hospitalier Universitaire de Nancy, Nancy, France.
Morschhauser F; Institute of Hematology-Transfusion, Centre Hospitalier Universitaire Régional de Lille, Lille, France.
Fruchart C; Service d'Hématologie, Institut d'Hématologie de Basse-Normandie, Centre Hospitalier Universitaire de Caen, Caen, France.
Daguindau N; Service d'Hématologie Clinique, Centre Hospitalier Annecy Genevois, Annecy, France.
van Eygen K; Oncologisch Centrum, AZ Groeninge Hospital, Kortrijk, Belgium.
Obéric L; Hôpital de Purpan, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Bouabdallah R; Department of Hematology, Institut Paoli Calmettes, Marseille, France.
Pica GM; Centre Hospitalier de Metropole Savoie, Chambery, France.
Nicolas-Virezelier E; Cancer Research Center of Lyon, Lyon, France.
Abraham J; Centre Hospitalier Universitaire Dupuytren, Limoges, France.
Fitoussi O; Hematology/Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.
Snauwaert S; AZ Sint-Jan Brugge-Oostende, Bruges, Belgium.
Eisenmann JC; Centre Hospitalier de Mulhouse, Mulhouse, France.
Lionne-Huyghe P; Centre Hospitalier d'Arras, Arras, France.
Bron D; Institut Jules Bordet, Brussels, Belgium.
Tricot S; Centre Hospitalier de Valenciennes, Valenciennes, France.
Deeren D; AZ Delta, Roeselare, Belgium.
Gonzalez H; Centre Hospitalier René-Dubos, Pontoise, France.
Costello R; Hôpital de la Conception, Marseille, France.
Le Du K; Clinique Victor Hugo, Le Mans, France.
da Silva MG; Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.
Grosicki S; Medical University of Silesia, Katowice, Poland.
Trotman J; Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.
Catalano J; Frankston Hospital and Monash University, Frankston, Vic., Australia.
Caballero D; Hospital Universitario de Salamanca, Salamanca, Spain.
Greil R; Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Salzburg, Austria.
Cohen AM; Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.
Gaulard P; University Hospital Henri Mondor APHP, Créteil, France.
Roulin L; Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France.
Takeshita K; Celgene Corporation, Summit, NJ, USA.
Casadebaig ML; Celgene Corporation, Boudry, Switzerland.
Tilly H; Department of Hematology, Centre Henri Becquerel, UNIROUEN, INSERMU1245, Rouen, France.
Coiffier B; Department of Hematology, INSERM U1052 Hospices Civils de Lyon, Pierre-Bénite, France.; Pokaż więcej
Źródło :: British journal of haematology [Br J Haematol] 2020 Apr; Vol. 189 (1), pp. 84-96. Date of Electronic Publication: 2019 Nov 08.
Typ publikacji :: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Maintenance Chemotherapy*
Quality of Life*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Lenalidomide/*administration & dosage
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Female ; Humans ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Vincristine/administration & dosage ; Vincristine/adverse effects
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""lenalidomide"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język